the trip is deemed critical.'X2 Use of antimicrobial agents has reduced the duration of diarrhea to an average of a little over 1 day compared to 4 or 5 days for untreated diarrhea.','
One approach to improved antidiarrheal efficacy has been the combined use of an antimicrobial agent and loperamide. In one study which was conducted in Mexico, where enterotoxigenic E. coli (ETEC) is the most common pathogen, the average duration of diarrhea treated with combination therapy was only 1 hour.3 This result equated with approximately 50% of the subjects not passing another unformed stool once therapy was begun. In this study the antimicrobial agent used was trimethoprim-sulfamethoxazole (TMP-SMX). The benefits of combination therapy were confirmed in a subsequent study, also conducted in Mexico, that examined the optimal regimen of dosingTMP-SMX when used with loperamide.4 Other studies that examined ciprofloxacin with loperamide either demonstrated a strong trend toward benefit only when ETEC was the prevalent pathogen, or failed to document the benefits of loperamide in shortening the duration of disease when Campylobacter was the prevalent p a t h~g e n .~.~ O n the other hand, ciprofloxacin plus loperamide proved more efficacious than ciprofloxacin alone in the treatment of dysentery caused largely by Shigella.' The present study was designed to determine the benefit of loperamide in combination with a fluoroquinolone, ofloxacin, in the same population in Mexico in which combination therapy with loperamide andTMP-SMX had been successful.
Methods
The subjects were adult students from the U.S. residing temporarily in Guadalajara, Mexico, during the summers of 1992-1 994.They were enrolled consecutively and randomly in the treatment study when they had passed at least three unformed stools in 24 hours and had at least one other symptom of enteric disease, such as abdominal cramps, nausea, vomiting or fever. No subject was excluded from possible enrollment because of severity of symptoms, including the passage of bloody stools. No subject had received an antimicrobial or antimotility agent prior to enrollment. Subjects received the following treatments orally: A) ofloxacin (400 mg as a single dose); B) ofloxacin (200 mg twice a day for 3 days); or C) ofloxacin (400 mg as a single dose) plus loperamide for up to 3 days (4 mg loading dose followed by 2 mg after each loose stool not to exceed 16 mg in a 24-hour period). The 200-mg dose of ofloxacin in group B was chosen based on unpublished data from the sponsor that stool levels of ofloxacin would be adequate at this dose to treat enteropathogens. All subjects remained in Mexico for the entire study period.
Prior to randomization, which was predetermined by a table of random numbers, all subjects submitted an unformed stool sample for analysis. Stools were processed in Guadalajara for the presence of parasites (Giardia, Entamoeba histolytica, and Cryptosporiditrm) and cultured for the presence of Shigella, Salmonella, Campylobacter, Pleisiomonas, Aeromonas, Vibrio spp. and Escherichia coli by standard culture techniques.8 Five E. coli-like colonies were picked for each stool sample and transported back to Houston for heat-stable and heat-labile enterotoxin testing. ' Subjects signed an informed consent before becoming aware of the drug regimen to which they were randomly assigned. Because of financial constraints, the study was not double blinded. Subjects kept daily diaries for 5 days and documented enteric symptoms, possible adverse reactions, and times when study medications were taken.They reported daily to the clinic for assessment of their progress. Subjects were declared treatment failures if their diarrhea worsened despite at least 24 hours of therapy. They were then removed from the protocol and treated at the discretion of the attending physician.
In the statistical analysis, a p-value of < .05 was considered significant, but in the three painvise comparisons of treatment eflicacy, significance was defined conservatively as p = .05/3 or p < .01. Baseline comparability of treatment groups was assessed by analysis of variance, the Kruskall-Wallis test and chi-square tests.The primary outcome parameter, which was time from initiation of therapy to passage of the last unformed stool (at which time subjects were considered well), was determined by a blinded evaluator who was unaware of the treatment group of the subjects. The last unformed stool was declared when the subject had passed no watery stools and no more than one soft stool for 24 hours in the absence of symptoms. The outcome analysis used the Kaplan-Meier life table method and generalized Wilcoxon's test. First, an assessment of efficacy was performed, excluding subjects who had not been compliant in keeping their diaries or taking their medication. Lack of compliance with medication was defined as missing a dose of ofloxacin (group B) or as failing to take loperamide after an unformed stool (all groups).Then all subjects were included in an intent-to-treat analysis.The sample sizes for this study were chosen based on previous experience with successful demonstration of efficacy of single dose or combination therapy.3,4 All subjects signed an informed consent document. The study was approved by the Committee for the Protection of Human Subjects at The University ofTexasHouston Health Science Center and by the Universities of San Diego and Arizona, whose programs the students were attending while in Guadalajara.
Results
One hundred and sixty-six subjects were enrolled and analyzed. Subjects in each treatment group were similar by age, sex, hours of illness prior to enrollment, number of unformed stools passed in the previous 24 hours, presence of enteric symptoms, and isolation of enteric pathogens (Table 1 ). Five subjects in group A, 4 in group B and 2 in group C were considered noncompliant. Because the efficacy analysis yielded the same results as the intent-to-treat analysis, only results of the latter will be reported here. Table 2 shows the median duration of diarrhea in various analyses. For all cases, as well as in the pathogen subgroups, treatment C (combination therapy) was significantly more efficacious than treatment A or B, except when Shigella was the cause of diarrhea, in which case no significant differences were seen. By definition, when tNo difference between treatment groups was statistically significant. *ETEC = enterotoxigenic E. coli the last unformed stool was passed the subjects were free of other diarrhea symptoms. Also, fever in all subjects abated during the first day of treatment. No differences between treatment groups A and B were significant. Table 3 shows the percent recovered over time. Again, in this analysis, treatment C was significantly more efficacious than treatment A or B, with 63% of subjects in group C passing no further unformed stools after beginning therapy, and 91% having recovered by the end of 1 day. Four treatment failures occurred in group A, two in group B and none in group C. No pathogen was isolated from any of these treatment failure cases. While these differences in treatment failures were not significant, they further support the efficacy of treatment with ofloxacin plus loperamide. No subject had a clinically important adverse reaction.
Discussion
These data support the previous observations by our group that an antimicrobial plus loperamide is more Table 2 Median Hours of Diarrhea After Treatment efficacious in the treatment of traveler's diarrhea than is treatment with an antimicrobial alone in a population in which ETEC and Shigella, but not Campylobacter, are relatively common pathogemwe have now documented this observation in two studies using TMP-SMX3,4 and in the present study using the fluoroquinolone, ofloxacin. The present study also confirms that the proportion of summertime traveler's diarrhea in Mexico caused by no identifiable bacterial pathogen responds to an antimicrobial and is likely caused by bacteria not assessed in the present study.
An obvious criticism of the present study is that it was not double blinded in traditional fashion due to financial constraints. In an attempt to minimize bias, subjects agreed to participate in the study before the drug regimen was revealed to them. Data were analyzed by a blinded evaluator without knowledge of the treatment groups. Subjects were enrolled consecutively and randomly, without regard to severity of illness, and no subject refused to participate. Subjects, not investigators, were responsible for recording the form and time of pass- ing of stools; these data form the basis for the primary outcome analysis.We doubt bias was introduced into the analysis by subjects, because all were told that they were on active therapy and that the main objective of the study was to demonstrate that no differences existed between the regimens. Another potential criticism of the study is that the 200-mg dose of ofloxacin might have been too low. In the present study the percentage of subjects treated with 200 mg twice a day for 3 days and becoming well by 24 and 48 hr was 45% and 73%, respectively.These figures compare favorably with results of a study of ofloxacin dosed at 300 mg twice daily in which the percentage well at 24 and 48 h, respectively, for 3-day therapy was 59% and 80% and for 5-day therapy was 41% and 72%." Likewise, when ciprofloxacin was dosed at 500 mg twice daily for 5 days, the percentage well at 24 and 48 h was 60% and 72%."
The results of the present study are supported by the findings of a study conducted inThailand that examined ciprofloxacin with and without loperamide in the treatment of dysentery caused primarily by Shigeffa.' Results showed that combination therapy was substantially and significantly more efficacious than treatment with ciprofloxacin alone. That study's results stand in contradistinction to the results of the study of Petruccelli et al.,5 in which the benefits of combination therapy with ciprofloxacin plus loperamide were not seen when Campybbacter was a relatively common cause of diarrhea.5 The study by Taylor et al.' suggests a marginal benefit for combination therapy, especially when ETEC is common.6 This entire body of knowledge tends to support arming travelers with both an antimicrobial and loperamide for self treatment of their diarrhea, but leaves in question whether to include loperamide in the optimal treatment for proven Campyfobacter disease.
Reassuringly, no study to date has suggested that the addition of loperamide to the treatment of Campylohacter disease by an antimicrobial would prolong the disease and thereby call into question the utility of combination therapy in the empiric or self treatment of traveler's diarrhea. In inland Mexico where the susceptibility of enteric pathogens toTMP-SMX remains relatively high," TMP-SMX should probably be preferred for the treatment of summertime diarrhea because the drug is inexpensive and Campylobacter is an uncommon cause of diarrhea during this season.' In most other areas of the world, where TMP-SMX susceptibility is much lower, and whenever Campylobacter is a common path~gen,'~ we feel the preferred antimicrobial is probably a fluoroquinolone such as ofloxacin, ciprofloxacin or norfloxacin.
The choice of specific fluoroquinolone should probably be made based on cost alone, as they all appear to be efficacious.'s2
The present study also supports the use of a single dose of an antimicrobial with loperamide in the treatment of traveler's diarrhea. One study that compared treatment with loperamide plus a single large dose ofTMP-SMX or the same large single dose followed by standard therapy for a total of 3 days demonstrated a significant difference in efficacy in favor of continuing therapy for 3 d a~s .~T h e benefit was not, however, clinically substantial. Unlike the results of a large study that demonstrated the benefit of loperamide combined with ciprofloxacin in the treatment of shigellosis,' the present study was unable to demonstrate a difference in the studied regimens in the treatment of shigellosis with all regimens performing well. One explanation is that we generally are able to intervene with therapy early in the course of shigellosis in its diarrheic phase; we see a dysenteric presentation in only about 10% of persons later proving to have shigellosis. Whether or not persons with shigellosis received loperamide in the present study, they recovered on average in less than a day. In several published studies, furthermore, shigellosis has been well treated by a single dose of an antimi~robial.',~*~ These data, taken as a whole, support the treatment of many if not most cases of traveler's diarrhea with a single dose of an antimicrobial (usually a fluoroquinolone) plus loperamide. Based on our experience with TMP-SMX, severe forms of traveler's diarrhea, including illness associated with important fever or passage of bloody stools, might best be treated with loperamide plus a loading dose of an antimicrobial followed by 3 days of continued treatment; however, data supporting this concept for fluoroquinolones and loperamide are presently lacking. Because use of loperamide alone as empiric therapy for traveler's diarrhea successfully treats many patients, some clinicians prefer to advise the patient to take loperamide first, especially ifdiarrhea is mild to moderate, then to take an antimicrobial only if relief is not forthcoming in the ensuing 24-48 hours. In our exper i e n~e ,~ approximately 17% of patients with traveler's diarrhea sick enough to qualitjl for a study will opt to take an antimicrobial because of inadequate relief, if loperamide alone is chosen as front-line therapy. In our minds, whether to treat all disease aggressively with combination therapy at the onset, or whether to adopt a stepwise approach to the use of loperamide and antimicrobials, is a matter ofjudgment. In our own travel clinic, the patient is invited to participate in the final decision about the self treatment of traveler's diarrhea using antimicrobials and loperamide.
